[wp-rss-aggregator feeds=”press-releases”]
Alzamend Neuro, Inc. (ALZN) Press Releases
- Alzamend Neuro Announces Reverse Stock Split July 12, 2024
- Alzamend Neuro Announces Favorable Decision from Nasdaq Hearings Panel May 22, 2024
- Alzamend Neuro Announces Initial Closing of Private Placement May 14, 2024
- Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million May 9, 2024
- Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program May 7, 2024
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients December 11, 2023
- Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients November 20, 2023
- Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement November 16, 2023
- Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001 November 13, 2023
- Alzamend Neuro Announces Reverse Stock Split October 30, 2023